Bladder Cancer Spread to Lymph Nodes

When bladder cancer spreads to lymph nodes, the symptoms often layer on top of what patients are already experiencing from their original tumour. The new signs can be easy to dismiss as just feeling run-down or stressed, which is exactly the problem.

Here are the warning signs that deserve immediate attention:

• Persistent pelvic pain that won’t settle: A dull, nagging ache in your lower belly or pelvis that doesn’t respond to usual painkillers. Enlarged nodes can press on nearby nerves and structures.
• Swelling in one or both legs: When pelvic lymph nodes get large, they can block the natural drainage system in your legs, causing swelling that doesn’t go down even after resting.
• New lower back or flank pain: Persistent pain that comes from deeper than muscle soreness, sometimes signalling that nodes higher up (near the kidneys) are involved.
• Losing weight without trying: A drop of even 3-5 kg over a couple of months without changing your eating habits is worth a concern.
• Feeling tired all the time: Not the usual end-of-day tired. The kind that doesn’t go away even after a full night’s sleep or weekend off.
• Loss of appetite or feeling full quickly: When even small meals feel like too much, it’s worth investigating.
• A lump in the groin or above the collarbone: Less common, but when it happens, it’s a clear signal the disease has travelled further.

If you’ve already been treated for bladder cancer and any of these symptoms creep in, don’t wait for your next scheduled follow-up.

• CT scan of abdomen and pelvis with contrast:Usually the first scan ordered. Good at spotting enlarged nodes (above 1 cm), but smaller affected nodes can slip through.
• MRI of the pelvis: Better than CT for seeing how deep the tumour has invaded the bladder wall, and for picking up smaller pelvic nodes. Often used when contrast CT isn’t an option.
• PET-CT scan: This one catches metabolically active disease that other scans miss. Especially useful for checking how well chemotherapy has worked, or when the initial imaging gives mixed signals.
• Bone scan: Ordered if there’s bone pain, abnormal blood tests, or signs that the cancer may have travelled beyond the lymph nodes.
• Cystoscopy with biopsy: Confirms what the primary tumour is doing and provides tissue for tests that guide which chemotherapy to use.
• Lymphadenectomy at surgery: The most accurate way to confirm involvement. Lymph nodes are physically removed during cystectomy and examined under a microscope.

Treatment is multimodal. Sequence matters as much as choice. Most fit patients receive systemic therapy first to shrink disease, followed by laparoscopic or robotic surgery, and sometimes additional therapy afterwards.

Step 1: Chemotherapy before surgery

Cisplatin-based chemotherapy is the standard starting point. It shrinks both the bladder tumour and involved nodes, and bumps up the chances of cure by 5-10 percent compared to surgery alone. Most patients need 3-4 cycles before the next step.

Step 2: Surgery

Once chemotherapy has done its work, surgery removes the bladder along with all the lymph nodes from the obturator fossa up to the common iliac vessels. This is the curative step for most patients with limited nodal involvement. For the full picture of what this surgery involves and the recovery, see our breakdown on radical cystectomy for bladder cancer.

Step 3: Therapy after surgery

For high-risk patients with residual disease at cystectomy, adjuvant nivolumab (immunotherapy) is now standard. Given for up to a year after surgery, it significantly extends the time before any recurrence.

When surgery isn’t possible

If surgery isn’t possible because disease has spread too widely, treatment shifts to chemotherapy followed by immunotherapy. Newer targeted therapies like FGFR inhibitors and enfortumab vedotin have extended survival for selected patients in recent years.

Outcomes depend heavily on how the cancer responds to that first round of chemotherapy. Complete nodal shrinkage pushes 5-year survival above 50 percent, and adjuvant immunotherapy now helps even when some disease remains. Most patients have CT or PET-CT every 3-6 months for two years, with surveillance continuing for at least 5 years to catch late recurrences early.